Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2010

Sapio Sciences to Supply LIMS to University of British Columbia

  • Sapio Sciences has entered into an agreement to supply the University of British Columbia’s Center for Molecular Medicine and Therpeutics (CMMT) Next Gen Sequencing Lab with its Exemplar Laboratory Information Management Solution (LIMS).

    CMMT plans to utilize Exemplar LIMS for sample management and integration with robotic platforms. The Examplar LIMS will support remote web-based sample submission and processing requests and automate storage management of samples, Sapio notes. Moreover, it will integrate with various laboratory devices to automate control of quantitation and hit-picking experiments, retrieve DNA extraction information, and implement workflows for genotyping and sequencing, the firm adds.

    “Exemplar excels at rapid implementation of instrument integrations, which can be combined with Examplar’s configurable ELN capability for a complete workflow that has automated instrument control and data capture,” says Julia Neel, chief software architect at Sapio.

    The University of British Columbia’s CMMT was founded in 1995 and explores the genetic basis of disease. It endeavors to translate what they learn into new treatment strategies for common and neglected diseases.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »